This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Maytal, J. Articles by King, K. C. Search for Related Content PubMed PubMed Citation Articles by Maytal, J. Articles by King, K. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PHENOBARBITAL Social Bookmarking                         What's this?

Lorazepam in the Treatment of Refractory Neonatal Seizures

Divisions of Pediatric Neurology and Neonatology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY, Long Island Campus for Albert Einstein College of Medicine

Gerald P. Novak, MD

Divisions of Pediatric Neurology and Neonatology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY, Long Island Campus for Albert Einstein College of Medicine

Katherine C. King, MD

Divisions of Pediatric Neurology and Neonatology, Schneider Children's Hospital, Long Island Jewish Medical Center, New Hyde Park, NY, Long Island Campus for Albert Einstein College of Medicine

We report the results of treatment of intractable seizures with lorazepam in seven neonates. All of the patients were part of a prospective study, who failed to respond to 40 mg/k of phenobarbital. Lorazepam was given intravenously at 0.05 mg/k and repeated up to a total dose of 0.15 mg/k if necessary. The diagnosis of seizures and the efficacy of treatment was assessed clinically and by EEG during the administration of lorazepam in three patients and on clinical grounds in four patients.

Six patients were full term and one was premature; there were five males and two females. Four patients had hypoxic-ischemic encephalopathy, two had intracranial hemorrhage, and one had bacterial meningitis.

Two patients received one dose of lorazepam, three received two doses, and two received three doses. Six patients responded with a complete cessation of seizures within three minutes of their last dose; the remaining patient (who received two doses) had a reduction in seizures.

No patients developed apnea or hypotension during or immediately after the infusion of lorazepam and no other adverse effects were observed. Four patients remained seizure-free for the rest of the neonatal period and no other anticonvulsant medications were added. Seizures recurred in one patient at 16 hours; subsequent intermittent seizures were managed with additional phenobarbital. In another patient, seizures recurred at 12 hours and subsequent intermittent seizures were managed with phenytoin. In one patient, seizures continued with reduction of frequency and duration.

We conclude that lorazepam may be effective in the treatment of neonatal seizures refractory to phenobarbital and that further treatment with intravenous phenytoin may be unnecessary under these circumstances. (J Child Neurol 1991;6:319-323).

Journal of Child Neurology, Vol. 6, No. 4, 319-323 (1991)
DOI: 10.1177/088307389100600406


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. J. Riviello Jr Pharmacology Review: Drug Therapy for Neonatal Seizures: Part 1 NeoReviews, May 1, 2004; 5(5): e215 - e220. [Full Text] [PDF]

				M Levene The clinical conundrum of neonatal seizures Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2002; 86(2): F75 - F77. [Abstract] [Full Text] [PDF]

				D. Evans and M. Levene Neonatal seizures Arch. Dis. Child. Fetal Neonatal Ed., January 1, 1998; 78(1): 70F - 75. [Full Text]